CAR T cells
Gilead to Pay Nearly $12B for CAR T-Cell Company
Gilead to Pay Nearly $12B for CAR T-Cell Company
Jef Akst | Aug 28, 2017
The massive sum will buy out Kite Pharma, whose cancer therapy is expected to be among the first of its type approved by the FDA.
The Ever-Expanding T-Cell World: A Primer
The Ever-Expanding T-Cell World: A Primer
Ashley P. Taylor | Aug 7, 2017
Researchers continue to identify new T-cell subtypes—and devise ways to use them to fight cancer. The Scientist attempts to catalog them all.
FDA Votes Yes on CAR T-Cell Therapy
FDA Votes Yes on CAR T-Cell Therapy
Aggie Mika | Jul 13, 2017
A Food and Drug Administration advisory panel unanimously calls for agency approval of the cell therapy for the treatment of resistant leukemia. 
CAR T-Cell Trials Boast Promising Results
CAR T-Cell Trials Boast Promising Results
Diana Kwon | Jun 5, 2017
The results of two small clinical trials show that the immunotherapy is effective for multiple myeloma patients, at least in the near term.
Making CAR T-Cell Therapy Safer
Making CAR T-Cell Therapy Safer
Catherine Offord | Apr 1, 2017
Following a spate of patient deaths in clinical trials testing modified T cells for the treatment of cancer, researchers work to reduce the treatment’s toxicity without sacrificing efficacy.
Hitting It Out of the Park
Hitting It Out of the Park
Mary Beth Aberlin | Apr 1, 2017
Cancer can be as evasive and slippery as a spitball, but new immunotherapies are starting to connect.
Kite’s CAR T-Cell Therapy Success
Kite’s CAR T-Cell Therapy Success
Jef Akst | Mar 1, 2017
More than one-third of lymphoma patients in a Phase 2 trial were clear of disease at six months, and no new safety concerns arose since the company’s three-month follow up.
Opinion: Balancing Risks and Rewards of CAR T-Cell Therapy
Opinion: Balancing Risks and Rewards of CAR T-Cell Therapy
David Harris | Dec 15, 2016
New approaches to treating cancer have shown great promise, but they also come with serious risks that give us cause for concern.
TS Picks: June 6, 2016
TS Picks: June 6, 2016
Jef Akst | Jun 6, 2016
American Society of Clinical Oncology meeting edition